Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALGS NASDAQ:APRE NASDAQ:GOSS NASDAQ:PYRGF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALGSAligos Therapeutics$4.08$5.50$3.98▼$13.69$25.25M2.26300,115 shs213,038 shsAPREAprea Therapeutics$0.62-1.2%$0.77$0.55▼$1.93$7.83M1.559,727 shs18,964 shsGOSSGossamer Bio$0.20+46.6%$0.18$0.11▼$3.87$31.92M2.0417.21 million shs317.35 million shsPYRGFPyroGenesis Canada$0.13-0.9%$0.17$0.12▼$0.53$32.51M0.2453,402 shs10,301 shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALGSAligos Therapeutics0.00%-28.92%-26.75%-36.55%-55.31%APREAprea Therapeutics0.00%-7.06%-20.00%-26.61%-66.56%GOSSGossamer Bio0.00%-20.14%-15.00%-60.98%-92.61%PYRGFPyroGenesis Canada0.00%-0.37%-7.95%-54.51%-55.03%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALGSAligos Therapeutics$4.08$5.50$3.98▼$13.69$25.25M2.26300,115 shs213,038 shsAPREAprea Therapeutics$0.62-1.2%$0.77$0.55▼$1.93$7.83M1.559,727 shs18,964 shsGOSSGossamer Bio$0.20+46.6%$0.18$0.11▼$3.87$31.92M2.0417.21 million shs317.35 million shsPYRGFPyroGenesis Canada$0.13-0.9%$0.17$0.12▼$0.53$32.51M0.2453,402 shs10,301 shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALGSAligos Therapeutics0.00%-28.92%-26.75%-36.55%-55.31%APREAprea Therapeutics0.00%-7.06%-20.00%-26.61%-66.56%GOSSGossamer Bio0.00%-20.14%-15.00%-60.98%-92.61%PYRGFPyroGenesis Canada0.00%-0.37%-7.95%-54.51%-55.03%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALGSAligos Therapeutics 2.86Moderate Buy$38.50843.63% UpsideAPREAprea Therapeutics 2.40Hold$4.07550.98% UpsideGOSSGossamer Bio 2.11Hold$3.201,504.81% UpsidePYRGFPyroGenesis Canada 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest APRE, GOSS, ALGS, and PYRGF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/27/2026GOSSGossamer Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy7/17/2026APREAprea Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)7/10/2026ALGSAligos Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/25/2026ALGSAligos Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/25/2026GOSSGossamer Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$5.00 ➝ $2.005/29/2026ALGSAligos Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight5/28/2026ALGSAligos Therapeutics Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$45.005/26/2026GOSSGossamer Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.005/21/2026ALGSAligos Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$20.005/21/2026ALGSAligos Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$20.005/19/2026GOSSGossamer Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)(Data available from 7/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALGSAligos Therapeutics$2.19M11.53N/AN/A$8.67 per share0.47APREAprea Therapeutics$290K26.67N/AN/A$1.52 per share0.41GOSSGossamer Bio$48.47M0.97N/AN/A($0.53) per share-0.38PYRGFPyroGenesis Canada$9.14M3.53N/AN/A($0.01) per share-13.19Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALGSAligos Therapeutics-$24.19M-$8.69N/AN/AN/A-1,919.68%-139.47%-90.88%8/5/2026 (Estimated)APREAprea Therapeutics-$12.60M-$1.54N/AN/AN/A-4,405.59%-61.03%-50.24%8/11/2026 (Estimated)GOSSGossamer Bio-$170.37M-$0.79N/AN/AN/A-324.82%N/A-96.10%8/4/2026 (Estimated)PYRGFPyroGenesis Canada-$21.12M-$0.04N/AN/AN/A-115.14%N/A-60.81%N/ALatest APRE, GOSS, ALGS, and PYRGF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2026Q2 2026APREAprea Therapeutics-$0.23N/AN/AN/A$0.25 millionN/A8/5/2026Q2 2026ALGSAligos Therapeutics-$1.41N/AN/AN/A$24.68 millionN/A8/4/2026Q2 2026GOSSGossamer Bio-$0.08N/AN/AN/A$4.30 millionN/A5/15/2026Q1 2026GOSSGossamer Bio-$0.17-$0.20-$0.03-$0.20$4.67 million$16.96 million5/13/2026Q1 2026APREAprea Therapeutics-$0.23-$0.22+$0.01-$0.22$0.00 millionN/A5/7/2026Q1 2026ALGSAligos Therapeutics-$2.29-$2.21+$0.08-$2.21$0.25 million$2.83 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALGSAligos TherapeuticsN/AN/AN/AN/AN/AAPREAprea TherapeuticsN/AN/AN/AN/AN/AGOSSGossamer BioN/AN/AN/AN/AN/APYRGFPyroGenesis CanadaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALGSAligos TherapeuticsN/A2.562.56APREAprea TherapeuticsN/A8.928.92GOSSGossamer BioN/A2.202.20PYRGFPyroGenesis CanadaN/A0.600.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALGSAligos Therapeutics60.43%APREAprea Therapeutics34.19%GOSSGossamer Bio81.23%PYRGFPyroGenesis Canada0.03%Insider OwnershipCompanyInsider OwnershipALGSAligos Therapeutics7.80%APREAprea Therapeutics10.49%GOSSGossamer Bio3.74%PYRGFPyroGenesis Canada47.68%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALGSAligos Therapeutics906.19 million5.71 millionNo DataAPREAprea Therapeutics712.38 million11.08 millionNo DataGOSSGossamer Bio180234.70 million225.92 millionOptionablePYRGFPyroGenesis Canada90244.28 million96.34 millionNo DataAPRE, GOSS, ALGS, and PYRGF HeadlinesRecent News About These CompaniesPyroGenesis Canada (NASDAQ:PYRGF) and Gemini Therapeutics (NASDAQ:GMTX) Head-To-Head SurveyJuly 27 at 2:15 AM | americanbankingnews.comPyroGenesis Reports Voting Results From 2026 Meeting of ShareholdersJune 23, 2026 | globenewswire.comPyroGenesis Delivers New Technology to Convert Contaminated Biomass to SyngasJune 17, 2026 | globenewswire.comP. Peter Pascali Updates Early Warning ReportJune 8, 2026 | globenewswire.comPyroGenesis Announces Closing of $2 Million Private PlacementJune 4, 2026 | globenewswire.comPyroGenesis Announces Closing of $6.26 Million in FinancingsJune 3, 2026 | globenewswire.comPyroGenesis Announces Upsize of Bought Deal LIFE Offering to $3.7 MillionMay 20, 2026 | globenewswire.comPyroGenesis Announces $3.0 Million Bought Deal LIFE Offering and Concurrent CEO Private Placement of up to $2.0 MillionMay 19, 2026 | newsfilecorp.comNPyroGenesis Announces a Binding Signed Contract to Acquire its Turcot Manufacturing FacilityMay 14, 2026 | globenewswire.comPyroGenesis Announces First Quarter 2026 Results: Revenue of $4.9 Million, Up 63% ...May 7, 2026 | caledonianrecord.comCPyroGenesis Announces First Quarter 2026 Results: Revenue of $4.9 Million, Up 63% Year-Over-Year for Best Quarter Since 2022May 7, 2026 | globenewswire.comPyroGenesis Schedules 2026 First Quarter Financial Results and Business Update Conference CallMay 1, 2026 | globenewswire.comPyroGenesis Provides Corporate Update on NexGen™ Titanium Metal Powder StrategyApril 29, 2026 | globenewswire.comPyroGenesis Announces Appointment of Jean Mayer as Vice-President, Legal Affairs and Corporate SecretaryApril 28, 2026 | globenewswire.comPyroGenesis Produces Battery-Grade Graphite from Carbon Black Using Proprietary Plasma SystemApril 23, 2026 | globenewswire.comPyroGenesis Announces Fourth Quarter and Full Year 2025 ResultsMarch 30, 2026 | globenewswire.comPyroGenesis Announces Closing of Non-Brokered Private PlacementMarch 26, 2026 | globenewswire.comPyroGenesis Schedules 2025 Fiscal Year Financial Results and Business Update Conference CallMarch 23, 2026 | globenewswire.comPyroGenesis Announces Oversubscription of Non-Brokered Private PlacementMarch 11, 2026 | globenewswire.comPyroGenesis Announces $1 Million Non-Brokered Private PlacementMarch 9, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAPRE, GOSS, ALGS, and PYRGF Company DescriptionsAligos Therapeutics NASDAQ:ALGS$4.08 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$4.08 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.Aprea Therapeutics NASDAQ:APRE$0.62 -0.01 (-1.16%) Closing price 03:59 PM EasternExtended Trading$0.62 -0.01 (-1.55%) As of 04:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.Gossamer Bio NASDAQ:GOSS$0.20 +0.06 (+46.62%) Closing price 04:00 PM EasternExtended Trading$0.28 +0.08 (+42.43%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.PyroGenesis Canada NASDAQ:PYRGF$0.13 0.00 (-0.90%) As of 12:43 PM EasternPyroGenesis Canada Inc. designs, develops, manufactures, and commercializes plasma processes and solutions worldwide. The company offers DROSRITE, a process for enhancing metal recovery from dross without any hazardous by-products; plasma atomization process that allows produce and sell high purity spherical metal powders; PUREVAP, a process to produce high purity metallurgical and solar grade silicon from quartz; and PUREVAP NSiR, which is designed to transform silicon into spherical silicon nano powders and nanowires for use in lithium-ion batteries. It provides plasma torches and plasma torch systems used toreplace fossil fuel burners in industrial iron ore pelletization process; plasma arc waste destruction systems for waste destruction onboard ships; steam plasma arc refrigerant cracking systems for the destruction of certain refrigerants, including chlorofluorocarbons, hydrofluorocarbons, and hydrochlorofluorocarbons; plasma arc chemical warfare agent destruction systems, which are mobile platforms for the onsite destruction of chemical warfare agents; plasma resource recovery systems for land-based waste destruction and waste-to-energy applications; plasma torches for waste gasification and combustion; and plasma arc gasification and vitrification. In addition, it offers engineering and manufacturing expertise, and contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, additive manufacturing (including 3D printing), oil and gas, and environmental industries. Further, the company provides installation, commissioning, and start-up services. PyroGenesis Canada Inc. is headquartered in Montreal, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dividend Stocks May Be the Quiet Rotation Trade Investors Are Missing Now AMD’s AI Bubble Could Burst Into Explosive Upside Refiner Stocks Are Near Record Highs—Can Iran-Driven Margins Keep Them There? A $1.5 Billion Wake-Up Call for Every AI Company on Wall Street AirJoule’s Kubota Deal Is a Major Validation—But the Hard Part Comes Next Atlassian’s AI Pivot Is Starting to Challenge Wall Street’s Bear Case Verizon May Be an AI Infrastructure Stock Hiding in Plain Sight Apple’s Earnings Setup Puts Its Record Rally and AI Patience to the Test Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
